PCK1 and ALDH1A1 are identified as biomarkers for inherent drug resistance in hepatocellular carcinoma
The findings suggest that PCK1 and ALDH1A1 may serve as potential biomarkers for predicting treatment response and guiding therapeutic strategies in HCC patients.
Authors
- Yong Yi (ORCID: https://orcid.org/0000-0003-0847-2590)
- Shuang–Jian Qiu (ORCID: https://orcid.org/0000-0003-2056-6127)
- Wei Chen (ORCID: https://orcid.org/0000-0002-6383-7540)
- Xinyu Wang (ORCID: https://orcid.org/0000-0002-9167-2077)
- Gao Liu (ORCID: https://orcid.org/0000-0003-2861-2431)
- Cheng Zhou (ORCID: https://orcid.org/0000-0001-9720-9318)
- Xu Yang (ORCID: https://orcid.org/0000-0003-2242-670X)
Institutions
- Sun Yat-sen University (CN)
- Fudan University (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Ministry of Education (ET)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1007/s12672-025-03481-4
- Citations
- 2
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 1.87
Funders
- National Natural Science Foundation of China